Baicalin

ID: baicalin

Aliases: baicalein glucuronide

Type: compound

Route/form: topical or route depends on product/study

Status: research_or_supplement

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 2

Broad outcomes: Hair / alopecia

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• canonical Wnt/beta-catenin signaling
• dermal papilla cell activation
• hair follicle development

Optimization domains

• hair
• androgenetic alopecia
• Wnt beta catenin
• natural product

Research basis

• Topical/reconstituted mouse follicle work links baicalin to Wnt/beta-catenin signaling and hair-follicle development.
• A separate human dermal papilla-cell plus mouse anagen-induction paper supports DP-cell activity, ALP, IGF-1/VEGF, and hair-cycle mechanism.
• This is a plausible hair-growth lead, but still a preclinical/topical-formulation story rather than a proved human AGA therapy.

Limits, risks, and missing evidence

• No robust human androgenetic-alopecia trial was identified.
• Topical formulation, penetration, local concentration, comparator strength, and chronic safety remain unresolved.
• Wnt/beta-catenin activation is a mechanism, not automatically a safe or durable hair-regrowth outcome.

Risk flags

• preclinical only
• topical delivery unknown
• limited human data
• hype risk

Linked papers, labels, and reviews

1. Baicalin increases hair follicle development via Wnt/beta-catenin signaling
   preclinical / pubmed_baicalin_hair_wnt_2018
   Mouse and dermal papilla cell hair-follicle mechanism source.
2. Baicalin, a flavonoid, affects the activity of human dermal papilla cells and promotes anagen induction in mice
   preclinical / pubmed_baicalin_dermal_papilla_2015
   Human dermal papilla-cell and mouse anagen-induction study; supports baicalin hair-growth mechanism while remaining non-human outcome evidence.